Shares of Invacare Co. (NYSE:IVC) have been assigned an average rating of “Hold” from the six brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $16.50.
IVC has been the subject of several research analyst reports. KeyCorp reissued a “buy” rating and set a $18.00 target price on shares of Invacare in a research note on Friday, November 10th. Zacks Investment Research raised Invacare from a “sell” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, ValuEngine raised Invacare from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st.
Several institutional investors have recently added to or reduced their stakes in the company. EAM Investors LLC acquired a new position in shares of Invacare in the fourth quarter valued at approximately $2,153,000. AlphaOne Investment Services LLC increased its stake in shares of Invacare by 0.8% in the fourth quarter. AlphaOne Investment Services LLC now owns 460,289 shares of the health services provider’s stock valued at $7,756,000 after buying an additional 3,532 shares during the period. Eversept Partners LLC acquired a new position in shares of Invacare in the fourth quarter valued at approximately $1,640,000. Royce & Associates LP increased its stake in shares of Invacare by 11.4% in the fourth quarter. Royce & Associates LP now owns 1,574,733 shares of the health services provider’s stock valued at $26,534,000 after buying an additional 160,564 shares during the period. Finally, UBS Asset Management Americas Inc. acquired a new position in shares of Invacare in the fourth quarter valued at approximately $234,000.
Invacare (NYSE:IVC) last issued its earnings results on Wednesday, February 7th. The health services provider reported ($0.42) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.02. The firm had revenue of $250.35 million during the quarter, compared to the consensus estimate of $241.07 million. Invacare had a negative return on equity of 14.95% and a negative net margin of 7.92%. The business’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.46) earnings per share. sell-side analysts forecast that Invacare will post -1.16 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, January 16th. Stockholders of record on Thursday, January 4th were paid a $0.0125 dividend. This represents a $0.05 annualized dividend and a dividend yield of 0.27%. The ex-dividend date was Wednesday, January 3rd. Invacare’s dividend payout ratio is currently -2.14%.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/13/invacare-co-ivc-receives-average-recommendation-of-hold-from-analysts.html.
Invacare Corporation is a manufacturer and distributor for medical equipment used in non-acute care settings. The Company’s geographical segments are Europe; North America, which includes North America/Home Medical Equipment (North America/HME) and Institutional Products Group (IPG) segments, and Asia/Pacific.
Receive News & Ratings for Invacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invacare and related companies with MarketBeat.com's FREE daily email newsletter.